The Board of Directors of Grifols recommends not supporting potential offer from Brookfield, as it undervalues the company
El Consejo de Administración de Grifols recomienda no apoyar la potencial oferta de Brookfield por infravalorar la empresa
Intel ID : 404323
| Synopsis |
|
The non-binding value indication given by Brookfield [TSX:BAM.A] was EUR 10.50 for each class A share, and EUR 7.62 for each class B share. These figures imply a company valuation of EUR 6.45bn. The response of the Board of Directors of Grifols [BME:GRF, GRF.P] follows the recommendation of the Transactions Committee established to analyze the potential PTO, which previously also advised against supporting Brookfield's offer at the indicated valuation.
(content in spanish)
La indicación de valor no vinculante trasladada por Brookfield [TSX:BAM.A] fue de EUR 10,50 por cada acción clase A, y de EUR 7,62 por cada acción clase B. Estas cifran implican una valoración de la empresa de EUR 6.450m. La respuesta del Consejo de Administración de Grifols [BME:GRF, GRF.P] sigue la recomendación del Comité de Transacciones creado para el análisis de la potencial OPA, que previamente también había recomendado no apoyar la oferta de Brookfield a la valoración indicada. |
Relevant Documents
| Notice / Relevant Fact | 19 Nov 2024 | Brookfield_Hecho_Relevante_2024.pdf | ES |
|
| Notice / Relevant Fact | 19 Nov 2024 | Grifols_Hecho_Relevante_2024.pdf | ES |
|
| Notice / Relevant Fact | 19 Nov 2024 | Grifols_Hecho_Relevante_2_2024.pdf | ES |
|
| Intel ID | 404323 | |||
| Value | EUR 6.450,00m (Approx.) | |||
| Native Currency | Euro (EUR) | |||
|
Financial Data - Grifols
(31 Dec 2023) |
Revenue: - EBITDA: - Net Debt: - |
|||
| Date |
 |
|||
| Country | |
|||
| Geography |  |
|||
| Subsector (Old TTR Sectors) |
|
|||
| Primary Subsector (TTRSC) |
25.01.01 Asset Management (Primary) 25 Financial Services / 25.01 Banking & Investment 30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|||
| Type |
|
|||
| Intel Grade |
|
|||
| Source |
|
|||
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.01 Asset Management 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.